CELLULARLINE SPA (CELL.MI) Fundamental Analysis & Valuation

BIT:CELL • IT0005244618

Current stock price

2.28 EUR
0 (0%)
Last:

This CELL.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. CELL.MI Profitability Analysis

1.1 Basic Checks

  • In the past year CELL has reported negative net income.
  • In the past year CELL had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: CELL reported negative net income in multiple years.
  • In the past 5 years CELL always reported a positive cash flow from operatings.
CELL.MI Yearly Net Income VS EBIT VS OCF VS FCFCELL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

1.2 Ratios

  • CELL's Return On Assets of -20.20% is on the low side compared to the rest of the industry. CELL is outperformed by 85.29% of its industry peers.
  • Looking at the Return On Equity, with a value of -36.26%, CELL is doing worse than 76.47% of the companies in the same industry.
  • The Return On Invested Capital of CELL (5.01%) is comparable to the rest of the industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for CELL is significantly below the industry average of 15.56%.
  • The 3 year average ROIC (2.92%) for CELL is below the current ROIC(5.01%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -20.2%
ROE -36.26%
ROIC 5.01%
ROA(3y)-5.63%
ROA(5y)-10.63%
ROE(3y)-10.27%
ROE(5y)-18.06%
ROIC(3y)2.92%
ROIC(5y)N/A
CELL.MI Yearly ROA, ROE, ROICCELL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40

1.3 Margins

  • CELL's Operating Margin of 3.42% is in line compared to the rest of the industry. CELL outperforms 44.12% of its industry peers.
  • CELL's Operating Margin has improved in the last couple of years.
  • CELL has a Gross Margin (40.98%) which is comparable to the rest of the industry.
  • CELL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 3.42%
PM (TTM) N/A
GM 40.98%
OM growth 3YN/A
OM growth 5Y31.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y-1.18%
CELL.MI Yearly Profit, Operating, Gross MarginsCELL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CELL.MI Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CELL is destroying value.
  • The number of shares outstanding for CELL has been reduced compared to 1 year ago.
  • CELL has less shares outstanding than it did 5 years ago.
  • CELL has a worse debt/assets ratio than last year.
CELL.MI Yearly Shares OutstandingCELL.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
CELL.MI Yearly Total Debt VS Total AssetsCELL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • CELL has an Altman-Z score of 2.94. This is not the best score and indicates that CELL is in the grey zone with still only limited risk for bankruptcy at the moment.
  • CELL has a Altman-Z score of 2.94. This is in the better half of the industry: CELL outperforms 67.65% of its industry peers.
  • CELL has a debt to FCF ratio of 2.29. This is a good value and a sign of high solvency as CELL would need 2.29 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 2.29, CELL is doing good in the industry, outperforming 76.47% of the companies in the same industry.
  • A Debt/Equity ratio of 0.15 indicates that CELL is not too dependend on debt financing.
  • CELL has a better Debt to Equity ratio (0.15) than 76.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.29
Altman-Z 2.94
ROIC/WACC0.68
WACC7.35%
CELL.MI Yearly LT Debt VS Equity VS FCFCELL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 2.20 indicates that CELL has no problem at all paying its short term obligations.
  • CELL has a Current ratio of 2.20. This is amongst the best in the industry. CELL outperforms 82.35% of its industry peers.
  • A Quick Ratio of 1.53 indicates that CELL should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.53, CELL is in the better half of the industry, outperforming 79.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 1.53
CELL.MI Yearly Current Assets VS Current LiabilitesCELL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CELL.MI Growth Analysis

3.1 Past

  • The earnings per share for CELL have decreased strongly by -764.12% in the last year.
  • CELL shows a decrease in Revenue. In the last year, the revenue decreased by -3.88%.
  • The Revenue has been growing by 8.42% on average over the past years. This is quite good.
EPS 1Y (TTM)-764.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-619.22%
Revenue 1Y (TTM)-3.88%
Revenue growth 3Y4.4%
Revenue growth 5Y8.42%
Sales Q2Q%-6.01%

3.2 Future

  • The Earnings Per Share is expected to grow by 2.99% on average over the next years.
  • The Revenue is expected to grow by 1.71% on average over the next years.
EPS Next Y0%
EPS Next 2Y2.99%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.9%
Revenue Next 2Y1.71%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CELL.MI Yearly Revenue VS EstimatesCELL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
CELL.MI Yearly EPS VS EstimatesCELL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

5

4. CELL.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CELL. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 6.77, the valuation of CELL can be described as very cheap.
  • CELL's Price/Forward Earnings ratio is rather cheap when compared to the industry. CELL is cheaper than 88.24% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of CELL to the average of the S&P500 Index (38.09), we can say CELL is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 6.77
CELL.MI Price Earnings VS Forward Price EarningsCELL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CELL is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
  • 100.00% of the companies in the same industry are more expensive than CELL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 3.63
EV/EBITDA 0.89
CELL.MI Per share dataCELL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.99%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. CELL.MI Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 4.76%, CELL is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.95, CELL pays a better dividend. On top of this CELL pays more dividend than 94.12% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.81, CELL pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.76%

5.2 History

  • The dividend of CELL decreases each year by -20.42%.
Dividend Growth(5Y)-20.42%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • CELL has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-5.54%
EPS Next 2Y2.99%
EPS Next 3YN/A
CELL.MI Yearly Income VS Free CF VS DividendCELL.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

More info and screens

Find the best dividend stocksShow peers with best dividend

CELL.MI Fundamentals: All Metrics, Ratios and Statistics

CELLULARLINE SPA

BIT:CELL (4/21/2026, 4:40:59 PM)

2.28

0 (0%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)03-09
Earnings (Next)05-05
Inst Owners4.94%
Inst Owner ChangeN/A
Ins Owners19.57%
Ins Owner ChangeN/A
Market Cap49.86M
Revenue(TTM)231.79M
Net Income(TTM)-35.05M
Analysts82.86
Price Target3.98 (74.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.76%
Yearly Dividend0.09
Dividend Growth(5Y)-20.42%
DP-5.54%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.88%
PT rev (3m)-4.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-21.43%
EPS NY rev (3m)-21.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.24%
Revenue NY rev (3m)-4.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.77
P/S 0.22
P/FCF 3.63
P/OCF 2.57
P/B 0.52
P/tB 0.79
EV/EBITDA 0.89
EPS(TTM)-1.68
EYN/A
EPS(NY)0.34
Fwd EY14.76%
FCF(TTM)0.63
FCFY27.54%
OCF(TTM)0.89
OCFY38.86%
SpS10.6
BVpS4.42
TBVpS2.88
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -20.2%
ROE -36.26%
ROCE 6.69%
ROIC 5.01%
ROICexc 6.28%
ROICexgc 9.75%
OM 3.42%
PM (TTM) N/A
GM 40.98%
FCFM 5.92%
ROA(3y)-5.63%
ROA(5y)-10.63%
ROE(3y)-10.27%
ROE(5y)-18.06%
ROIC(3y)2.92%
ROIC(5y)N/A
ROICexc(3y)3.5%
ROICexc(5y)N/A
ROICexgc(3y)7.94%
ROICexgc(5y)N/A
ROCE(3y)3.89%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y44.53%
ROICexc growth 3YN/A
ROICexc growth 5Y73.05%
OM growth 3YN/A
OM growth 5Y31.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y-1.18%
F-Score5
Asset Turnover1.34
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.29
Debt/EBITDA 0.22
Cap/Depr 10.1%
Cap/Sales 2.44%
Interest Coverage 250
Cash Conversion 30.36%
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 1.53
Altman-Z 2.94
F-Score5
WACC7.35%
ROIC/WACC0.68
Cap/Depr(3y)28.42%
Cap/Depr(5y)23.36%
Cap/Sales(3y)3.31%
Cap/Sales(5y)3.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-764.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-619.22%
EPS Next Y0%
EPS Next 2Y2.99%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.88%
Revenue growth 3Y4.4%
Revenue growth 5Y8.42%
Sales Q2Q%-6.01%
Revenue Next Year0.9%
Revenue Next 2Y1.71%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.14%
EBIT growth 3YN/A
EBIT growth 5Y43.02%
EBIT Next Year47.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.36%
FCF growth 3Y266.02%
FCF growth 5Y64.61%
OCF growth 1Y-9.99%
OCF growth 3Y58.25%
OCF growth 5Y11.38%

CELLULARLINE SPA / CELL.MI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CELLULARLINE SPA (CELL.MI) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CELL.MI.


What is the valuation status for CELL stock?

ChartMill assigns a valuation rating of 5 / 10 to CELLULARLINE SPA (CELL.MI). This can be considered as Fairly Valued.


How profitable is CELLULARLINE SPA (CELL.MI) stock?

CELLULARLINE SPA (CELL.MI) has a profitability rating of 3 / 10.


How financially healthy is CELLULARLINE SPA?

The financial health rating of CELLULARLINE SPA (CELL.MI) is 7 / 10.


Can you provide the dividend sustainability for CELL stock?

The dividend rating of CELLULARLINE SPA (CELL.MI) is 5 / 10 and the dividend payout ratio is -5.54%.